Skip to main content
OpenTrials
Completed

NCT Number: NCT02650700

Spleen Radiotherapy Decreases Severe CIT in Advanced NSCLC (SPLEENIR)

Chemotherapy is one of the main treatments for advanced NSCLC. However, chemotherapy induced thrombocytopenia (CIT) is one of the most important limitations for subsequent chemotherapy of cancer.

Although platelet transfusion is the gold standard to treat severe CIT, its clinical application is limited due to many disadvantages, such as short time for storage, not easy to save, the risk of infection and immunological diseases. What's more, other cytokines including IL-11 and rhTPO, are not so useful in clinical work. It is necessary to explore a new therapeutic method to treat CIT.

Researches show that spleen resection could improve the count of PLT. In this clinical trial, we design chemotherapy plus spleen radiotherapy to the subjects with advanced NSCLC, simultaneously, who underwent grade II or worse CIT. The primary endpoint is the incidence of severe CIT (≧grade III) in subsequent chemotherapy, the second endpoints are recovery time from bone marrow suppression and progression free survival, and the exploring index is the immulogical status.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Chemotherapy in Non-Small Cell Lung Cancer

Age range

18 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients with advanced (Stage IIIA or IIIB AJCC 7) NSCLC that was histologically or cytologically inoperable
  • ECOG whole body status (performancestatus,PS) level 0 or 1
  • The estimated survival time is more than 12 weeks, 18 ~75 years old
  • Laboratory results within 2 weeks prior to radiotherapy met the following criteria: ① Neutrophil count > 1,500/ MCL Heathko-Pilot Oncology Research Fund; ② Platelet > 50,000/ MCL; ③ Total bilirubin < 1.5 times of the normal upper limit value; ④AST(SGOT)/ALT(SGPT) < 2.5 times of the normal upper limit; ⑤ Serum creatinine < 1.5 times of the normal upper limit value; ⑥ The results of coagulation function examination were within the normal range
  • Women of childbearing age must have taken reliable contraceptive measures or conducted pregnancy tests (serum or urine) within 7 days before admission, and the results are negative, and are willing to use appropriate methods of contraception during the trial period and 8 weeks after the last administration of the trial drug. For men, they must agree to use appropriate methods of contraception or surgical sterilization during the trial period and 8 weeks after the last administration of the trial drug
  • Understand and voluntarily sign written informed consent
  • The investigator judged that the patient had good compliance

Exclusion criteria

  • Patients with serious functional damage of important organs;
  • Patients diagnosed adequately with other malignant tumors;
  • Pregnant or lactating women;
  • Patients in an active period of acute or chronic infectious diseases;
  • Combined with the disease of connective tissue
  • Patients who are allergic to any drugs or people with allergies;
  • Patients who participate in other clinical trials concurrently;
  • Brain metastases without being controlled;
  • With immunologic thrombocytopenia；
  • Excluding thrombocytopenia caused by other reasons(Non chemotherapeutic agents, such as heparin, etc.);
  • The degree of tumor thrombus >2;
  • Patients who are considered not eligible for the trial after evaluation by investigator.

Treatment and study plan

spleen radiotherapy

Radiation

Radiation: spleen radiation In Experimental arm, combine spleen radiation with chemotherapy. In Chemotherapy alone arm, the subjects should also receive spleen radiation once there is a severe CIT (≧grade III) during chemotherapy after radomization.

Other names: IMRT

Primary outcomes

  1. The incidence of severe CIT afer chemotherapy

    Time frame: 18 weeks after randomization

Secondary outcomes

  1. Recovery time after severe bone marrow suppression

    Time frame: 18 weeks after randomization

  2. Progression free suvival (PFS)

    Time frame: Time Frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 20 months

  3. Objective response rate (ORR)

    Time frame: Time Frame: 18 weeks after randomization

Sponsors and collaborators

Lead sponsor

Xinqiao Hospital of Chongqing

Other

Registry information

Official study title

Spleen Radiotherapy Decreases Severe Chemotherapy Induced Thrombocytopenia (CIT) for the Multi-center Randomized Controlled Study in Advanced NSCLC

Important dates

Study start
2016
Primary completion
2020
Study completion
2020
First posted
Jan 8, 2016
Registry last updated
Aug 1, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.